These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25281420)

  • 21. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.
    Zhang Y; Li Y; Fu Q; Han Z; Wang D; Umar Shinge SA; Muluh TA; Lu X
    Curr Cancer Drug Targets; 2023; 23(4):251-264. PubMed ID: 36278447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
    Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapy comes of age.
    Topalian SL; Weiner GJ; Pardoll DM
    J Clin Oncol; 2011 Dec; 29(36):4828-36. PubMed ID: 22042955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE; Caenepeel S; Wu LC
    Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment duration with immune-based therapies in Cancer: an enigma.
    Bantia S; Choradia N
    J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives.
    Washah HN; Salifu EY; Soremekun O; Elrashedy AA; Munsamy G; Olotu FA; Soliman MES
    Comb Chem High Throughput Screen; 2020; 23(8):687-698. PubMed ID: 32338212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.
    Childs RW; Carlsten M
    Nat Rev Drug Discov; 2015 Jul; 14(7):487-98. PubMed ID: 26000725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.
    Baghdadi M; Takeuchi S; Wada H; Seino K
    MAbs; 2014; 6(5):1124-32. PubMed ID: 25517298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
    Demaria O; Gauthier L; Debroas G; Vivier E
    Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted cancer immunotherapy.
    Zigler M; Shir A; Levitzki A
    Curr Opin Pharmacol; 2013 Aug; 13(4):504-10. PubMed ID: 23648271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies in cancer immunotherapy.
    Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C
    Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
    Graciotti M; Berti C; Klok HA; Kandalaft L
    J Transl Med; 2017 Jun; 15(1):142. PubMed ID: 28629381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the global dynamics of a model for tumor immunotherapy.
    Kirschner D; Tsygvintsev A
    Math Biosci Eng; 2009 Jul; 6(3):573-83. PubMed ID: 19566127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the Effects of Chemotherapy and Immunotherapy on Tumor Growth.
    El Haout S; Fatani M; Farha NA; AlSawaftah N; Mortula M; Husseini GA
    J Biomed Nanotechnol; 2021 Dec; 17(12):2505-2518. PubMed ID: 34974873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.